Affinia Therapeutics advances AFTX-201 gene therapy for BAG3 dilated cardiomyopathy
Affinia Therapeutics gains FDA orphan status for AFTX-201 as the UPBEAT trial tests gene therapy for BAG3 dilated cardiomyopathy.
Pharma & Biotech
Pharma & Biotech
PharmaEssentia wins Health Canada approval for BESREMi in polycythemia vera
Read how Health Canada’s BESREMi approval could reshape polycythemia vera treatment, reimbursement and PharmaEssentia’s Canadian strategy.
Pharma & Biotech
Apotex Sevmia challenges Wegovy as generic GLP-1 competition begins in Canada
Read how Apotex’s Sevmia approval could reshape Canada’s semaglutide market, and why dosing, pricing and reimbursement still matter.
Medical Devices & Diagnostics
KixCare brings pediatric physical exams home with Nonagon’s 9-in-1 diagnostic device
Kix360° Vitals combines Nonagon’s N9+ remote examination device with round-the-clock pediatric virtual care, but affordability, caregiver technique and clinical escalation will determine whether it genuinely reduces unnecessary hospital visits.
Pharma & Biotech
Optimi Health’s first UK psilocybin export signals bigger test for GMP psychedelic manufacturing
Find out how Optimi Health’s UK psilocybin export could reshape psychedelic trial supply and what risks remain for Phase 2 research.
Pharma & Biotech
Phoenix and Raven launch direct-to-patient generic semaglutide after Health Canada approval
Generic semaglutide is cheaper, but access is now the real battleground. Phoenix and Raven are testing Canada’s GLP-1 telehealth future.
Pharma & Biotech
Dr. Reddy’s moves first in Canada’s generic semaglutide market. Can access improve?
GLP-1 demand is booming, but access remains uneven. Dr. Reddy’s Canada launch tests whether generics can change semaglutide economics.
Pharma & Biotech
Why Apotex’s Apo-Semaglutide approval could reshape Canada’s diabetes drug market
Canada has generic Ozempic momentum. Apotex’s approval turns GLP-1 access into a pricing and supply-chain test.
Pharma & Biotech
Coya Therapeutics expands ALS trial into Canada as COYA 302 gains Health Canada clearance
Coya Therapeutics expands its ALS trial for COYA 302 to Canada after Health Canada clearance. Explore what this means for the biotech’s immunotherapy platform.
Pharma & Biotech
Spiderwort Biotechnologies’ cellulose scaffolds show promise in spinal cord repair
Spiderwort’s spinal cord scaffold earns scientific validation as its dermal filler enters human trials Spiderwort Biotechnologies Inc. has reported two key developments in its cellulose-based regenerative platform, signaling a step forward in both neurorepair and aesthetic medicine. A peer-reviewed study published in Scientific Reports confirms that the company’s plant-derived scaffolds promote neural tissue repair and